2023 年第 7 期 第 18 卷

信迪利单抗联合安罗替尼治疗晚期非小细胞肺癌的效果及安全性

The efficacy and safety of sintilimab combined with androtini in the treatment of advanced non-small cell lung cancer

作者：李亚茹单美华韩亚光梁欢张淼张燕

英文作者：Li Yaru Shan Meihua Han Yaguang Liang Huan Zhang Miao Zhang Yan

单位：石家庄市人民医院肿瘤内科，石家庄050000

英文单位：Department of Medical Oncology Shijiazhuang People′s Hospital Shijiazhuang 050000 China

关键词：非小细胞肺癌；信迪利单抗；安罗替尼

英文关键词：Non-smallcelllungcancer;Sintilimab;Anlotinib

• 摘要：

• 目的  探讨信迪利单抗联合安罗替尼治疗晚期非小细胞肺癌（NSCLC）的效果及安全性。方法  收集2018年6月至2021年1月石家庄市人民医院收治的既往均接受过一线或多线治疗的晚期NSCLC患者27例的临床资料，患者均给予信迪利单抗联合安罗替尼治疗。评估临床疗效，分析无进展生存期（PFS）的影响因素，记录不良反应发生情况。结果  27例患者中位随访时间为10.6个月，部分缓解2例，疾病稳定18例，疾病进展7例，客观有效率为7.4%（2/27），疾病控制率为74.1%（20/27）。多因素Cox回归分析结果显示，美国东部肿瘤协作组体能状态评分0～1分（风险比=8.817，95%置信区间：1.913～40.641，P=0.005）和高白蛋白（≥34.5 g/L）（风险比=9.936，95%置信区间：2.167～45.567，P=0.003）患者PFS更优。27例患者中18例（66.7%）发生与抗肿瘤治疗相关的不良反应，除1例高血压为3级外，其余均为1～2级。结论  信迪利单抗联合安罗替尼治疗晚期NSCLC疗效较好，且耐受性良好。体力评分及营养状况良好者获益更明显。

• Objective  To investigate the efficacy and safety of sintilimab combined with androtini in the treatment of advanced non-small cell lung cancer (NSCLC). Methods  From June 2018 to January 2021, the clinical data of 27 patients with advanced NSCLC who had previously received first-line or multiple treatment in Shijiazhuang People′s Hospital were collected, and all patients were treated with sintilimab combined with androtini. The clinical efficacy was evaluated, the influencing factors of progression-free survival (PFS) were analyzed, and the occurrence of adverse reactions were recorded. Results  The median follow-up time of 27 patients was 10.6 months, with partial remission in 2 cases, disease stability in 18 cases and disease progression in 7 cases. The objective effective rate was 7.4% (2/27), and the disease control rate was 74.1% (20/27). The results of multivariate Cox regression analysis showed that the PFS of patients with Eastern Cooperative Oncology Group performance status score of 0 to 1 (hazard ratio=8.817, 95% confidence interval: 1.913-40.641, P=0.005) and high albumin (≥34.5 g/L) (hazard ratio=9.936, 95% confidence interval: 2.167-45.567, P=0.003) were better. Of the 27 patients, 18 cases (66.7%) had adverse reactions related to anti-tumor therapy and the others, except for 1 case of grade 3 hypertension, were grade 1 to 2. Conclusions    intilimab combined with anlotinib has good efficacy and tolerability in the treatment of advanced NSCLC. Those with good physical strength scores and nutritional status benefit more significantly.